Intrarenal dopamine inhibits progression of diabetic nephropathy

Diabetes

Volumn 61, Issue 10, 2012, Pages 2575-2584

  Zhang, Ming Zhi ^a,b   Yao, Bing ^a   Yang, Shilin ^a   Yang, Haichun ^b   Wang, Suwan ^a   Fan, Xiaofeng ^a   Yin, Huiyong ^a   Fogo, Agnes B ^b   Moeckel, Gilbert W ^c   Harris, Raymond C ^a,b,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE; CYCLOOXYGENASE 2; DOPAMINE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME DEFICIENCY; EXPERIMENTAL MODEL; FIBROSIS; GLOMERULOPATHY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULTRAFILTRATION;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; CATECHOL O-METHYLTRANSFERASE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOPAMINE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, KNOCKOUT; RENIN-ANGIOTENSIN SYSTEM;

EID: 84866618859     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0046     Document Type: Article

References (43)

1. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007;34:36-41 (Pubitemid 46069583)
2. Komers R, Lindsley JN, Oyama TT, et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001;107:889-898 (Pubitemid 32274042)
3. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002;62:929-939 (Pubitemid 35316722)
4. Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001;23:321-330 (Pubitemid 32694392)
5. Aperia AC. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 2000;62:621-647 (Pubitemid 30618277)
6. Zeng C, Sanada H, Watanabe H, Eisner GM, Felder RA, Jose PA. Functional genomics of the dopaminergic system in hypertension. Physiol Genomics 2004;19:233-246
7. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 1996;97:2745-2752 (Pubitemid 26197089)
8. Zeng C, Yang Z, Wang Z, et al. Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells. Hypertension 2005;45:804-810 (Pubitemid 40418385)
9. Yang Z, Asico LD, Yu P, et al. D5 dopamine receptor regulation of reactive oxygen species production, NADPH oxidase, and blood pressure. Am J Physiol Regul Integr Comp Physiol 2006;290:R96-R104
10. Zhang MZ, Yao B, McKanna JA, Harris RC. Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems. Am J Physiol Renal Physiol 2005;288:F840-F845 (Pubitemid 40381754)
11. Yao B, Harris RC, Zhang MZ. Intrarenal dopamine attenuates deoxycorticosterone acetate/high salt-induced blood pressure elevation in part through activation of a medullary cyclooxygenase 2 pathway. Hypertension 2009;54:1077-1083
12. Zhang MZ, Yao B, Fang X, Wang S, Smith JP, Harris RC. Intrarenal dopaminergic system regulates renin expression. Hypertension 2009;53:564-570
13. Zhang MZ, Yao B, Wang S, et al. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest 2011;121:2845-2854
14. Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 2001;281:F1-F11
15. Carranza A, Karabatas L, Barontini M, Armando I. Decreased tubular uptake of L-3,4-dihydroxyphenylalanine in streptozotocin-induced diabetic rats. Horm Res 2001;55:282-287 (Pubitemid 34114175)
16. Marwaha A, Banday AA, Lokhandwala MF. Reduced renal dopamine D1 receptor function in streptozotocin-induced diabetic rats. Am J Physiol Renal Physiol 2004;286:F451-F457 (Pubitemid 38233637)
17. Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999;10:2569-2576
18. Thomson SC, Vallon V, Blantz RC. Kidney function in early diabetes: the tubular hypothesis of glomerular filtration. Am J Physiol Renal Physiol 2004;286:F8-F15 (Pubitemid 38045037)
19. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase- deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998;95:9991-9996 (Pubitemid 28415282)
20. Qi Z, Whitt I, Mehta A, et al. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 2004;286:F590-F596 (Pubitemid 38233654)
21. Perez FA, Palmiter RD. Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005;102:2174-2179 (Pubitemid 40262031)
22. Murphey LJ, Morrow JD, Sawathiparnich P, Williams GH, Vaughan DE, Brown NJ. Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. Free Radic Biol Med 2003;35:711-718 (Pubitemid 37329474)
23. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997;36:1-21 (Pubitemid 27387112)
24. Zhang MZ, Yao B, Cheng HF, Wang SW, Inagami T, Harris RC. Renal cortical cyclooxygenase 2 expression is differentially regulated by angiotensin II AT(1) and AT(2) receptors. Proc Natl Acad Sci USA 2006;103:16045-16050 (Pubitemid 44657589)
25. Qi Z, Fujita H, Jin J, et al. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 2005;54:2628-2637 (Pubitemid 41233584)
26. Brosius FC 3rd, Alpers CE, Bottinger EP, et al.; Animal Models of Diabetic Complications Consortium. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009;20:2503-2512
27. Breyer MD, Böttinger E, Brosius FC 3rd, et al.; AMDCC. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45 (Pubitemid 43073154)
28. Eklöf AC, Holtbäck U, Sundelöf M, Chen S, Aperia A. Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na+,K+-ATPase. Kidney Int 1997;52:742-747 (Pubitemid 27402374)
29. Vieira-Coelho MA, Gomes P, Serrão MP, Soares-da-Silva P. D1-like dopamine receptor activation and natriuresis by nitrocatechol COMT inhibitors. Kidney Int 2001;59:1683-1694 (Pubitemid 32336783)
30. Lal MA, Körner A, Matsuo Y, et al. Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats. Diabetes 2000;49:1381-1389 (Pubitemid 30624240)
31. Yao B, Xu J, Qi Z, Harris RC, Zhang MZ. Role of renal cortical cyclooxygenase-2 expression in hyperfiltration in rats with high-protein intake. Am J Physiol Renal Physiol 2006;291:F368-F374 (Pubitemid 44148127)
32. Wang J-L, Cheng H-F, Sheppel S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000;57:2334-2342 (Pubitemid 30340732)
33. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011;6:395-423
34. Pelayo JC, Shanley PF. Glomerular and tubular adaptive responses to acute nephron loss in the rat. Effect of prostaglandin synthesis inhibition. J Clin Invest 1990;85:1761-1769 (Pubitemid 20192947)
35. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998;275:F613-F622
36. Barthelmebs M, Vailly B, Velly J, Grima M, Imbs JL. L-dopa and streptozotocin-induced diabetic nephropathy in rats. Am J Hypertens 1990;3:72S-74S (Pubitemid 20380227)
37. Barthelmebs M, Vailly B, Grima M, et al. Effects of dopamine prodrugs and fenoldopam on glomerular hyperfiltration in streptozotocin-induced diabetes in rats. J Cardiovasc Pharmacol 1991;18:243-253
38. Umrani DN, Goyal RK. Beneficial effects of fenoldopam treatment on renal function in streptozotocin-induced diabetic rats. Clin Exp Hypertens 2002; 24:207-219 (Pubitemid 34194121)
39. Ibarra FR, Armando I, Nowicki S, et al. Dopamine is metabolised by different enzymes along the rat nephron. Pflugers Arch 2005;450:185-191 (Pubitemid 40897632)
40. Chan JC, Critchley JA, Ho CS, Nicholls MG, Cockram CS, Swaminathan R. Atrial natriuretic peptide and urinary dopamine output in non-insulin-dependent diabetes mellitus. Clin Sci (Lond) 1992;83:247-253
41. Stenvinkel P, Saggar-Malik AK, Wahrenberg H, Diczfalusy U, Bolinder J, Alvestrand A. Impaired intrarenal dopamine production following intravenous sodium chloride infusion in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991;34:114-118
42. Lee MR. Dopamine and the kidney: ten years on. Clin Sci (Lond) 1993; 84:357-375 (Pubitemid 23113942)
43. Endlich N, Endlich K. cAMP pathway in podocytes. Microsc Res Tech 2002;57:228-231 (Pubitemid 34553254)